Individuals with novel coronavirus disease 2019 (COVID-19) who have familial hypercholesterolemia (FH) may be at higher risk for cardiac complications and atherosclerotic cardiovascular disease (ASCVD) in the long-term, according to study results published in the Journal of Internal Medicine.

FH is characterized by a lifelong a 2- to 3-fold increase in plasma low-density lipoprotein-cholesterol concentration. If left untreated, FH may lead to premature ASCVD and a higher risk for acute coronary events during middle age.

A significant proportion of patients with COVID-19 in Wuhan, China, were men aged 40 to 60 years, with comorbidities in approximately one-third.

Patients with COVID-19 and FH were found to be at increased risk for cardiac complications compared with patients with COVID-19 but no FH. Of the 138 patients hospitalized with COVID-19 in Wuhan, 25% had cardiovascular disease and 58% had hypertension. Of the patients with COVID-19 who did not require to be treated in intensive care units, 10% and 22% had cardiovascular disease and hypertension, respectively.

Continue Reading

Related Articles

COVID-19 infections may result in long-term adverse abnormalities in lipid and glucose metabolism as well as chronic Chlamydia pneumoniae infection which has been associated with an increased risk for coronary artery disease in individuals with FH. Patients with FH may be at increased risk of developing an atherothrombotic event during and after COVID-19 infection. Cholesterol-lowering regimens should be intensified in patients with FH and COVID-19, as the virus may affect endothelial function in the coronary artery. In addition, treatments with statins and PCSK9 inhibitors should be continued.

”[P]harmacotherapy for severe hypercholesterolemia in [a patient with FH and] COVID‐19 should not be discontinued during infection and, due to possible excess risk [for] ASCVD, could even be intensified following recovery from COVID‐19,” concluded the study authors.


Vuorio A, Watts GF, Kovanen PT. Familial hypercholesterolemia and COVID-19: triggering of increased sustained cardiovascular risk [published online April 3, 2020]. J Intern Med. doi:10.1111/joim.13070

This article originally appeared on The Cardiology Advisor